Merck invests in Italian biotech manufacturing site
Science and technology company, Merck, is investing €35 million in a new production line for the aseptic filling of biotech medicines under isolator at its Bari, Italy, manufacturing site.
“This investment underpins the importance of the Modugno-Bari production site for our growing Healthcare business,” said Stefan Oschmann, chairman of the Executive Board and CEO of Merck. “It will help us to secure the supply of medicines that improve people's lives around the world.”
The new production line was announced as a part of an event celebrating the 25th anniversary of the Italian site and is expected to be fully operational in 2022. The line will be equipped with an isolator designed with the most recent technologies and automation capabilities. It is intended to be used for the aseptic filling of Merck’s biotech medicines in the areas of multiple sclerosis, fertility and endocrinology with a capacity of 14 million units per year.